Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2...(za vaccine distributed worldwideand in t...)

Date:7/31/2008

za vaccine distributed worldwide and in the U.S. produced more than 40 percent of the influenza vaccine distributed for the 2007-2008 influenza season. Sanofi Pasteur is committed to raising immunization rates and improving global access to vaccines. As part of this commitment, the company is expanding its influenza vaccine production facility in the United States. This expansion, slated to come on-line to produce vaccine for the 2009-2010 season, will more than double sanofi pasteur's U.S. production capacity.

"As a manufacturer, one of our primary objectives is to be responsive to the requests of our customers for early influenza vaccine shipments. In planning their vaccination efforts, it is important for health-care providers and the public to realize that while influenza immunization programs often occur in the early fall, the influenza season itself does not typically peak until February, with disease appearing as late as May. This allows many months for providers to administer influenza vaccine to their patients," said Pisano.

Influenza Immunization Recommendations

The CDC recommends that health-care providers begin offering influenza vaccine as soon as vaccine becomes available, and continue immunization efforts throughout the season. Health-care providers are urged to continue immunization efforts until the end of influenza season. Approximately 250 million people, or 4 out of 5 residents of the U.S., are recommended to receive the influenza vaccine annually. The CDC recommends an annual influenza immunization for anyone who wishes to reduce their risk of contracting influenza; children 6 months through 18 years of age; adults over 50 years of age; pregnant women; and anyone with chronic health conditions, such as asthma, chronic obstructive pulmonary disease (COPD), heart disease, and diabetes. The CDC also recommends annual immunization for caregivers and household contacts of these high-risk groups; such as relatives and health-care
'/>"/>

SOURCE Sanofi Pasteur Copyright©2008 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
2. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
3. Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America
4. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
5. Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis
6. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
7. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
8. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
9. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
10. Pasteuria Bioscience Taps New CEO David N. Duncan
11. SPO Medical Begins Shipping PulseOx 6000(TM) and PulseOx 6100(TM)